Age Related Macular Degeneration Market By Drug Type , By Disease Type (Wet Age Related Macular Degeneration , Dry Age Related Macular Degeneration ) By Distribution Channel : Global Opportunity Analysis and Industry Forecast, 2024-2033
노인황반변성 시장
노인황반변성 시장은 2023년 100억 달러로 평가되며 2024년부터 2033년까지 CAGR 5%로 성장하여 2033년에는 162억 달러에 달할 것으로 예상됩니다.
노인황반변성은 황반으로 알려진 망막의 중심부가 악화되는 시각 장애입니다. 약간의 흐릿한 시야로 시작하여 결국 중심 시력을 잃게 됩니다. 이 질병에는 건성(위축성)과 습성(혈관 신생)의 두 가지 범주가 있습니다. 건성 황반변성은 황반이 점차 얇아지는 반면, 습성 황반변성은 망막 아래 혈관이 비정상적으로 증식하여 발생합니다.
노령화 인구의 기하급수적인 증가와 유병률의 증가는 연령 관련 황반변성 시장의 주요 촉진요인입니다. 또한, 진단 기술의 발전은 질병의 조기 발견과 적시 치료로 이어져 시장 개척을 촉진하고 있습니다. 최근에는 AI와 딥러닝이 황반변성 진단 및 치료 상황에 혁명을 불러일으키고 있습니다. 이 기술은 눈의 상태를 정확하게 감지하고 질병이 진행될 경우 위험을 평가하는 데 도움이 될 수 있습니다.
그러나 병기가 많이 진행된 경우, 치료법이 제한적인 효과를 보여 노인황반변성 시장의 성장을 저해하고 있습니다. 또한, 항혈관내피성장인자 주사와 같이 질병을 치료하는 데 필수적인 약물을 구입하는 데 드는 비용이 비싸기 때문에 치료를 받지 못하는 환자도 있습니다. 이는 시장 개척에 걸림돌이 되고 있습니다. 영국 과학저널 출판사 바이오메드 센트럴(BioMed Central)이 발표한 논문에 따르면, 노인황반변성은 시력 저하의 주요 원인 중 하나이며, 2040년까지 2억 8,800만 명에게 영향을 미칠 것으로 예측됩니다.
부문별 리뷰
노인황반변성 시장은 약물 유형, 질병 유형, 유통 채널, 지역으로 구분됩니다. 약물 유형은 아플리버셉트, 라니비주맙, 기타로 나뉩니다. 질환 유형별로는 습성 연령관련 황반변성(AMD)과 건성 연령관련 황반변성(AMD)으로 나뉩니다. 판매 채널별로는 병원 약국, 소매 약국, 온라인 약국으로 나뉩니다. 지역별로는 북미, 유럽, 아시아태평양, LAMEA로 분석됩니다.
주요 조사 결과
약물 유형별로는 아플리버셉트 부문이 노인황반변성 시장을 독점하고 있습니다.
질환 유형별로는 습성 연령관련 황반변성(AMD) 부문이 가장 큰 시장 점유율을 차지하고 있습니다.
판매 채널별로는 병원 약국 부문이 시장을 주도하고 있습니다.
지역별로 보면 시장은 북미에서 강력한 성장세를 보이고 있습니다.
이 보고서는 사용자 정의가 가능합니다.
- 규제 가이드라인
- 고객의 관심사에 맞는 기업 프로파일 추가
- 기업 개요 확장 목록
- 과거 시장 데이터
목차
제1장 소개
제2장 주요 요약
제3장 시장 상황
- 시장 정의와 범위
- 주요 조사 결과
- Porter's Five Forces 분석
- 시장 역학
제4장 노인황반변성 시장 : 약물 유형별
- 시장 개요
- Aflibercept
- Ranibizumab
- 기타
제5장 노인황반변성 시장 : 질환 유형별
- 시장 개요
- 습성 노인황반변성(AMD)
- 건성 노인황반변성(AMD)
제6장 노인황반변성 시장 : 유통 채널별
제7장 시장 개요 노인황반변성 시장 : 지역별
- 시장 개요
- 북미
- 주요 시장 동향과 기회
- 미국의 노인황반변성 시장
- 캐나다의 노인황반변성 시장
- 멕시코 노인황반변성 시장
- 유럽
- 주요 시장 동향과 기회
- 프랑스의 노인황반변성 시장
- 독일의 노인황반변성 시장
- 이탈리아의 노인황반변성 시장
- 스페인의 노인황반변성 시장
- 영국의 노인황반변성 시장
- 기타 유럽의 노인황반변성 시장
- 아시아태평양
- 주요 시장 동향과 기회
- 중국의 노인황반변성 시장
- 일본의 노인황반변성 시장
- 인도의 노인황반변성 시장
- 한국의 노인황반변성 시장
- 호주의 노인황반변성 시장
- 기타 아시아태평양의 노인황반변성 시장
- 라틴아메리카, 중동 및 아프리카
- 주요 시장 동향과 기회
- 브라질의 노인황반변성 시장
- 남아프리카공화국의 노인황반변성 시장
- 사우디아라비아의 노인황반변성 시장
- 기타 라틴아메리카, 중동 및 아프리카 노인황반변성 시장
제8장 경쟁 상황
- 소개
- 주요 성공 전략
- 주요 10개 기업 제품 매핑
- 경쟁 대시보드
- 경쟁 히트맵
- 주요 기업의 포지셔닝(2023년)
제9장 기업 개요
- Regeneron Pharmaceuticals Inc.
- Novartis AG
- F. Hoffmann-La Roche Ltd.
- Biogen
- Bayer AG
- Coherus Biosciences Inc
- Sanofi
- Apellis Pharmaceuticals
- Bausch Health Companies Inc.
- Ionis Pharmaceuticals, Inc
ksm
Age Related Macular Degeneration Market
The age related macular degeneration market was valued at $10.0 billion in 2023 and is projected to reach $16.2 billion by 2033, growing at a CAGR of 5% from 2024 to 2033.
Age related macular degeneration is a visual impairment in which the central portion of the retina, known as macula, deteriorates. Beginning with slight blurred vision, the disease eventually leads to loss of central eyesight. There are two categories of the disease: dry (atrophic) and wet (neovascular). Gradual thinning of the macula occurs in dry macular degeneration, whereas wet macular degeneration happens due to abnormal growth of blood vessels under the retina.
Exponential increase in the aging population and rise in prevalence of the disease are the key drivers of the age related macular degeneration market. In addition, advancements in diagnostic techniques are leading to early detection and timely treatment of the disease, thereby augmenting the market development. In recent times, AI and deep learning are revolutionizing the landscape of age related macular degeneration diagnosis and treatment. The technology helps in precise detection of the eye condition and assesses the risk pertaining to the progression of the disease to advanced stages.
However, in case of disease advancement to high stages, treatment procedures exhibit limited to no efficacy, thereby restraining the growth of the age related macular degeneration market. Moreover, the high expense of purchasing medications essential for curing the disease, such as anti-vascular endothelial growth factor injections, constraints several patients from undergoing the treatment. This hampers the development of the market. According to an article published by the UK-based scientific journals publisher-BioMed Central- age related macular degeneration is one of the leading causes of vision loss and by 2040, the disease is anticipated to impact 288 million individuals.
Segment Review
The age related macular degeneration market is segmented into drug type, disease type, distribution channel, and region. On the basis of drug type, the market is divided into aflibercept, ranibizumab, and others. Depending on disease type, it is bifurcated into wet age related macular degeneration (AMD) and dry age related macular degeneration (AMD). As per distribution channel, it is classified into hospital pharmacy, retail pharmacy, and online pharmacy. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Key Findings
On the basis of drug type, the aflibercept segment dominates the age related macular degeneration market.
Depending on disease type, the wet age-related macular degeneration (AMD) segment acquires a significant share of the market.
As per distribution channel, the hospital pharmacy segment leads in the market.
Region wise, the market exhibits robust growth in North America.
Competition Analysis
The leading players operating in the global age related macular degeneration market include Regeneron Pharmaceuticals Inc., Novartis AG, F. Hoffmann-La Roche Ltd., Biogen, Bayer AG, Coherus Biosciences Inc, Sanofi, Apellis Pharmaceuticals, Bausch Health Companies Inc., and Ionis Pharmaceuticals, Inc. These major players have adopted various key development strategies such as business expansion, new product launches, and partnerships, to strengthen their foothold in the competitive market.
Additional benefits you will get with this purchase are:
- Quarterly Update and* (only available with a corporate license, on listed price)
- 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
- Free Upcoming Version on the Purchase of Five and Enterprise User License.
- 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
- 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
- Free data Pack on the Five and Enterprise User License. (Excel version of the report)
- Free Updated report if the report is 6-12 months old or older.
- 24-hour priority response*
- Free Industry updates and white papers.
Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)
- Regulatory Guidelines
- Additional company profiles with specific to client's interest
- Expanded list for Company Profiles
- Historic market data
Key Market Segments
By Drug Type
- Aflibercept
- Ranibizumab
- Others
By Disease Type
- Wet Age Related Macular Degeneration (AMD)
- Dry Age Related Macular Degeneration (AMD)
By Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
By Region
- North America
- Europe
- France
- Germany
- Italy
- Spain
- UK
- Rest of Europe
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Rest of Asia-Pacific
- LAMEA
- Brazil
- South Africa
- Saudi Arabia
- Rest of LAMEA
Key Market Players:
- Regeneron Pharmaceuticals Inc.
- Novartis AG
- F. Hoffmann-La Roche Ltd.
- Biogen
- Bayer AG
- Coherus Biosciences Inc
- Sanofi
- Apellis Pharmaceuticals
- Bausch Health Companies Inc.
- Ionis Pharmaceuticals, Inc
TABLE OF CONTENTS
CHAPTER 1: INTRODUCTION
- 1.1. Report Description
- 1.2. Key Market Segments
- 1.3. Key Benefits
- 1.4. Research Methodology
- 1.4.1. Primary Research
- 1.4.2. Secondary Research
- 1.4.3. Analyst Tools and Models
CHAPTER 2: EXECUTIVE SUMMARY
CHAPTER 3: MARKET LANDSCAPE
- 3.1. Market Definition and Scope
- 3.2. Key Findings
- 3.2.1. Top Investment Pockets
- 3.2.2. Top Winning Strategies
- 3.3. Porter's Five Forces Analysis
- 3.3.1. Bargaining Power of Suppliers
- 3.3.2. Threat of New Entrants
- 3.3.3. Threat of Substitutes
- 3.3.4. Competitive Rivalry
- 3.3.5. Bargaining Power among Buyers
- 3.4. Market Dynamics
- 3.4.1. Drivers
- 3.4.2. Restraints
- 3.4.3. Opportunities
CHAPTER 4: AGE RELATED MACULAR DEGENERATION MARKET, BY DRUG TYPE
- 4.1. Market Overview
- 4.1.1 Market Size and Forecast, By Drug Type
- 4.2. Aflibercept
- 4.2.1. Key Market Trends, Growth Factors and Opportunities
- 4.2.2. Market Size and Forecast, By Region
- 4.2.3. Market Share Analysis, By Country
- 4.3. Ranibizumab
- 4.3.1. Key Market Trends, Growth Factors and Opportunities
- 4.3.2. Market Size and Forecast, By Region
- 4.3.3. Market Share Analysis, By Country
- 4.4. Others
- 4.4.1. Key Market Trends, Growth Factors and Opportunities
- 4.4.2. Market Size and Forecast, By Region
- 4.4.3. Market Share Analysis, By Country
CHAPTER 5: AGE RELATED MACULAR DEGENERATION MARKET, BY DISEASE TYPE
- 5.1. Market Overview
- 5.1.1 Market Size and Forecast, By Disease Type
- 5.2. Wet Age Related Macular Degeneration (AMD)
- 5.2.1. Key Market Trends, Growth Factors and Opportunities
- 5.2.2. Market Size and Forecast, By Region
- 5.2.3. Market Share Analysis, By Country
- 5.3. Dry Age Related Macular Degeneration (AMD)
- 5.3.1. Key Market Trends, Growth Factors and Opportunities
- 5.3.2. Market Size and Forecast, By Region
- 5.3.3. Market Share Analysis, By Country
CHAPTER 6: AGE RELATED MACULAR DEGENERATION MARKET, BY DISTRIBUTION CHANNEL
- 6.1. Market Overview
- 6.1.1 Market Size and Forecast, By Distribution Channel
- 6.2. Hospital Pharmacy
- 6.2.1. Key Market Trends, Growth Factors and Opportunities
- 6.2.2. Market Size and Forecast, By Region
- 6.2.3. Market Share Analysis, By Country
- 6.3. Retail Pharmacy
- 6.3.1. Key Market Trends, Growth Factors and Opportunities
- 6.3.2. Market Size and Forecast, By Region
- 6.3.3. Market Share Analysis, By Country
- 6.4. Online Pharmacy
- 6.4.1. Key Market Trends, Growth Factors and Opportunities
- 6.4.2. Market Size and Forecast, By Region
- 6.4.3. Market Share Analysis, By Country
CHAPTER 7: AGE RELATED MACULAR DEGENERATION MARKET, BY REGION
- 7.1. Market Overview
- 7.1.1 Market Size and Forecast, By Region
- 7.2. North America
- 7.2.1. Key Market Trends and Opportunities
- 7.2.2. Market Size and Forecast, By Drug Type
- 7.2.3. Market Size and Forecast, By Disease Type
- 7.2.4. Market Size and Forecast, By Distribution Channel
- 7.2.5. Market Size and Forecast, By Country
- 7.2.6. U.S. Age Related Macular Degeneration Market
- 7.2.6.1. Market Size and Forecast, By Drug Type
- 7.2.6.2. Market Size and Forecast, By Disease Type
- 7.2.6.3. Market Size and Forecast, By Distribution Channel
- 7.2.7. Canada Age Related Macular Degeneration Market
- 7.2.7.1. Market Size and Forecast, By Drug Type
- 7.2.7.2. Market Size and Forecast, By Disease Type
- 7.2.7.3. Market Size and Forecast, By Distribution Channel
- 7.2.8. Mexico Age Related Macular Degeneration Market
- 7.2.8.1. Market Size and Forecast, By Drug Type
- 7.2.8.2. Market Size and Forecast, By Disease Type
- 7.2.8.3. Market Size and Forecast, By Distribution Channel
- 7.3. Europe
- 7.3.1. Key Market Trends and Opportunities
- 7.3.2. Market Size and Forecast, By Drug Type
- 7.3.3. Market Size and Forecast, By Disease Type
- 7.3.4. Market Size and Forecast, By Distribution Channel
- 7.3.5. Market Size and Forecast, By Country
- 7.3.6. France Age Related Macular Degeneration Market
- 7.3.6.1. Market Size and Forecast, By Drug Type
- 7.3.6.2. Market Size and Forecast, By Disease Type
- 7.3.6.3. Market Size and Forecast, By Distribution Channel
- 7.3.7. Germany Age Related Macular Degeneration Market
- 7.3.7.1. Market Size and Forecast, By Drug Type
- 7.3.7.2. Market Size and Forecast, By Disease Type
- 7.3.7.3. Market Size and Forecast, By Distribution Channel
- 7.3.8. Italy Age Related Macular Degeneration Market
- 7.3.8.1. Market Size and Forecast, By Drug Type
- 7.3.8.2. Market Size and Forecast, By Disease Type
- 7.3.8.3. Market Size and Forecast, By Distribution Channel
- 7.3.9. Spain Age Related Macular Degeneration Market
- 7.3.9.1. Market Size and Forecast, By Drug Type
- 7.3.9.2. Market Size and Forecast, By Disease Type
- 7.3.9.3. Market Size and Forecast, By Distribution Channel
- 7.3.10. UK Age Related Macular Degeneration Market
- 7.3.10.1. Market Size and Forecast, By Drug Type
- 7.3.10.2. Market Size and Forecast, By Disease Type
- 7.3.10.3. Market Size and Forecast, By Distribution Channel
- 7.3.11. Rest of Europe Age Related Macular Degeneration Market
- 7.3.11.1. Market Size and Forecast, By Drug Type
- 7.3.11.2. Market Size and Forecast, By Disease Type
- 7.3.11.3. Market Size and Forecast, By Distribution Channel
- 7.4. Asia-Pacific
- 7.4.1. Key Market Trends and Opportunities
- 7.4.2. Market Size and Forecast, By Drug Type
- 7.4.3. Market Size and Forecast, By Disease Type
- 7.4.4. Market Size and Forecast, By Distribution Channel
- 7.4.5. Market Size and Forecast, By Country
- 7.4.6. China Age Related Macular Degeneration Market
- 7.4.6.1. Market Size and Forecast, By Drug Type
- 7.4.6.2. Market Size and Forecast, By Disease Type
- 7.4.6.3. Market Size and Forecast, By Distribution Channel
- 7.4.7. Japan Age Related Macular Degeneration Market
- 7.4.7.1. Market Size and Forecast, By Drug Type
- 7.4.7.2. Market Size and Forecast, By Disease Type
- 7.4.7.3. Market Size and Forecast, By Distribution Channel
- 7.4.8. India Age Related Macular Degeneration Market
- 7.4.8.1. Market Size and Forecast, By Drug Type
- 7.4.8.2. Market Size and Forecast, By Disease Type
- 7.4.8.3. Market Size and Forecast, By Distribution Channel
- 7.4.9. South Korea Age Related Macular Degeneration Market
- 7.4.9.1. Market Size and Forecast, By Drug Type
- 7.4.9.2. Market Size and Forecast, By Disease Type
- 7.4.9.3. Market Size and Forecast, By Distribution Channel
- 7.4.10. Australia Age Related Macular Degeneration Market
- 7.4.10.1. Market Size and Forecast, By Drug Type
- 7.4.10.2. Market Size and Forecast, By Disease Type
- 7.4.10.3. Market Size and Forecast, By Distribution Channel
- 7.4.11. Rest of Asia-Pacific Age Related Macular Degeneration Market
- 7.4.11.1. Market Size and Forecast, By Drug Type
- 7.4.11.2. Market Size and Forecast, By Disease Type
- 7.4.11.3. Market Size and Forecast, By Distribution Channel
- 7.5. LAMEA
- 7.5.1. Key Market Trends and Opportunities
- 7.5.2. Market Size and Forecast, By Drug Type
- 7.5.3. Market Size and Forecast, By Disease Type
- 7.5.4. Market Size and Forecast, By Distribution Channel
- 7.5.5. Market Size and Forecast, By Country
- 7.5.6. Brazil Age Related Macular Degeneration Market
- 7.5.6.1. Market Size and Forecast, By Drug Type
- 7.5.6.2. Market Size and Forecast, By Disease Type
- 7.5.6.3. Market Size and Forecast, By Distribution Channel
- 7.5.7. South Africa Age Related Macular Degeneration Market
- 7.5.7.1. Market Size and Forecast, By Drug Type
- 7.5.7.2. Market Size and Forecast, By Disease Type
- 7.5.7.3. Market Size and Forecast, By Distribution Channel
- 7.5.8. Saudi Arabia Age Related Macular Degeneration Market
- 7.5.8.1. Market Size and Forecast, By Drug Type
- 7.5.8.2. Market Size and Forecast, By Disease Type
- 7.5.8.3. Market Size and Forecast, By Distribution Channel
- 7.5.9. Rest of LAMEA Age Related Macular Degeneration Market
- 7.5.9.1. Market Size and Forecast, By Drug Type
- 7.5.9.2. Market Size and Forecast, By Disease Type
- 7.5.9.3. Market Size and Forecast, By Distribution Channel
CHAPTER 8: COMPETITIVE LANDSCAPE
- 8.1. Introduction
- 8.2. Top Winning Strategies
- 8.3. Product Mapping of Top 10 Player
- 8.4. Competitive Dashboard
- 8.5. Competitive Heatmap
- 8.6. Top Player Positioning, 2023
CHAPTER 9: COMPANY PROFILES
- 9.1. Regeneron Pharmaceuticals Inc.
- 9.1.1. Company Overview
- 9.1.2. Key Executives
- 9.1.3. Company Snapshot
- 9.1.4. Operating Business Segments
- 9.1.5. Product Portfolio
- 9.1.6. Business Performance
- 9.1.7. Key Strategic Moves and Developments
- 9.2. Novartis AG
- 9.2.1. Company Overview
- 9.2.2. Key Executives
- 9.2.3. Company Snapshot
- 9.2.4. Operating Business Segments
- 9.2.5. Product Portfolio
- 9.2.6. Business Performance
- 9.2.7. Key Strategic Moves and Developments
- 9.3. F. Hoffmann-La Roche Ltd.
- 9.3.1. Company Overview
- 9.3.2. Key Executives
- 9.3.3. Company Snapshot
- 9.3.4. Operating Business Segments
- 9.3.5. Product Portfolio
- 9.3.6. Business Performance
- 9.3.7. Key Strategic Moves and Developments
- 9.4. Biogen
- 9.4.1. Company Overview
- 9.4.2. Key Executives
- 9.4.3. Company Snapshot
- 9.4.4. Operating Business Segments
- 9.4.5. Product Portfolio
- 9.4.6. Business Performance
- 9.4.7. Key Strategic Moves and Developments
- 9.5. Bayer AG
- 9.5.1. Company Overview
- 9.5.2. Key Executives
- 9.5.3. Company Snapshot
- 9.5.4. Operating Business Segments
- 9.5.5. Product Portfolio
- 9.5.6. Business Performance
- 9.5.7. Key Strategic Moves and Developments
- 9.6. Coherus Biosciences Inc
- 9.6.1. Company Overview
- 9.6.2. Key Executives
- 9.6.3. Company Snapshot
- 9.6.4. Operating Business Segments
- 9.6.5. Product Portfolio
- 9.6.6. Business Performance
- 9.6.7. Key Strategic Moves and Developments
- 9.7. Sanofi
- 9.7.1. Company Overview
- 9.7.2. Key Executives
- 9.7.3. Company Snapshot
- 9.7.4. Operating Business Segments
- 9.7.5. Product Portfolio
- 9.7.6. Business Performance
- 9.7.7. Key Strategic Moves and Developments
- 9.8. Apellis Pharmaceuticals
- 9.8.1. Company Overview
- 9.8.2. Key Executives
- 9.8.3. Company Snapshot
- 9.8.4. Operating Business Segments
- 9.8.5. Product Portfolio
- 9.8.6. Business Performance
- 9.8.7. Key Strategic Moves and Developments
- 9.9. Bausch Health Companies Inc.
- 9.9.1. Company Overview
- 9.9.2. Key Executives
- 9.9.3. Company Snapshot
- 9.9.4. Operating Business Segments
- 9.9.5. Product Portfolio
- 9.9.6. Business Performance
- 9.9.7. Key Strategic Moves and Developments
- 9.10. Ionis Pharmaceuticals, Inc
- 9.10.1. Company Overview
- 9.10.2. Key Executives
- 9.10.3. Company Snapshot
- 9.10.4. Operating Business Segments
- 9.10.5. Product Portfolio
- 9.10.6. Business Performance
- 9.10.7. Key Strategic Moves and Developments
